SG11201908905SA - Cryopreservation method - Google Patents
Cryopreservation methodInfo
- Publication number
- SG11201908905SA SG11201908905SA SG11201908905SA SG11201908905SA SG 11201908905S A SG11201908905S A SG 11201908905SA SG 11201908905S A SG11201908905S A SG 11201908905SA SG 11201908905S A SG11201908905S A SG 11201908905SA
- Authority
- SG
- Singapore
- Prior art keywords
- sol
- hbtscs
- medium
- international
- rome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
Abstract
B00 9140 80,00 ._= =-• 7000 50,00 M1A0 30,00 20,00 10 ,00 00 SOL 1 SOL IA SOL 3 NO CPO MEDIUM 0 10.00 9.00 8.00 1.00 6.00 .7:: 5.00 M 4.00 3.00 2.00 1.00 0.00 SOLI SOL 3 NO CRY0 MEDIUM A 10, 0, 00 0 9 —80,0 60,0 50,00 4000 • = 1 30,00 20,00 10,00 0,0 SOLI 50L3 NO MO MEDIUM E 45 E 40 35 =s 330 25 nl.:\" 20 5 CTRL SOL MO SOL 2A SOL 2B 01.3 1 NO MEDIUM C 1.20 1.00 5.0.80 MI.60 9 0.40 :F2 0.20 0.00 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT Iiiimmomitiaotiolomolmomomil moiflom (10) International Publication Number WO 2018/187439 Al (51) International Patent Classification: A01N 1/02 (2006.01) A61K 47/20 (2006.01) A61K 38/38 (2006.01) C12N 5/00 (2006.01) (21) International Application Number: PCT/US2018/026038 (22) International Filing Date: 04 April 2018 (04.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/482,644 06 April 2017 (06.04.2017) US (71) Applicants: THE UNIVERSITY OF NORTH CAR- OLINA AT CHAPEL HILL [US/US]; Office of Com- mercialization and Economic Development, 109 Church Street, Chapel Hill, North Carolina 27516 (US). SAPIEN- ZA UNIVERSITA DI ROMA [IT/IT]; Piazzale Aldo Mo- ro, No. 9, 00185 Roma (IT). (72) Inventors: REID, Lola M.; 3621 Sweeten Creek Road, Chapel Hill, North Carolina 27514 (US). DOMENICO, Al- varo; Via Giuseppe Vasi 18, 00162 Rome (IT). CARDI- NALE, Vincenzo; Viale Regina Margherita, 00171 Rome (IT). GAUDIO, Eugenio; Via G. Tuccimei, 1, 00197 Rome (IT). CARPINO, Guido; Viale Arrigo Boito, 61, 00199 Rome (IT). (74) Agent: VILLACORTA, Gilberto M. et al.; FOLEY & LARDNER LLP, 3000 K Street NM., Suite 600, Washing- ton, District of Columbia 20007-5109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (54) Title: CRYOPRESERVATION METHOD 1-1 N co 00 O C SOL 1 SOL 3 MEDIUM FIGS. 1A-1E (57) : Human biliary tree stem/progenitors (hBTSCs) are being used for cell therapies of patients with liver cirrhosis. A cryopreservation method was established to optimize sourcing of hBTSCs for these clinical programs and that comprises serum-free Kubota's Medium (KM) supplemented with 10% dimethyl sulfoxide (DMSO), -3% recombinant human albumin and 0.1% hyaluronans. Cryopreserved versus freshly isolated hBTSCs were similar in vitro with respect to self-replication, sternness traits, and multipotency. They were able to differentiate to functional hepatocytes, cholangiocytes or pancreatic islets, yielding similar levels of secretion of albumin or of glucose-inducible levels of insulin. Cryopreserved versus freshly isolated hBTSCs were equally able to engraft into immunocompromised mice yielding cells with human-specific gene expression and human albumin levels in murine serum that were higher for cryopreserved than for freshly isolated hBTSCs. The successful cryoypreservation of hBTSCs facilitates establishment of [Continued on next page] WO 2018/187439 Al IMEDIMOMOIDEIREI0131MOBIEHOMEMOIMIE CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) hBTSCs cell banking offering logistical advantages for clinical programs for treatment of liver disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762482644P | 2017-04-06 | 2017-04-06 | |
PCT/US2018/026038 WO2018187439A1 (en) | 2017-04-06 | 2018-04-04 | Cryopreservation method |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908905SA true SG11201908905SA (en) | 2019-10-30 |
Family
ID=63712283
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202111093PA SG10202111093PA (en) | 2017-04-06 | 2018-04-04 | Cryopreservation method |
SG11201908905S SG11201908905SA (en) | 2017-04-06 | 2018-04-04 | Cryopreservation method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202111093PA SG10202111093PA (en) | 2017-04-06 | 2018-04-04 | Cryopreservation method |
Country Status (12)
Country | Link |
---|---|
US (2) | US20180295834A1 (en) |
EP (1) | EP3612027A4 (en) |
JP (1) | JP2020516257A (en) |
KR (1) | KR20190141168A (en) |
CN (1) | CN110913691A (en) |
AU (1) | AU2018249853A1 (en) |
BR (1) | BR112019020699A2 (en) |
CA (1) | CA3057883A1 (en) |
IL (1) | IL269602B (en) |
RU (1) | RU2019135079A (en) |
SG (2) | SG10202111093PA (en) |
WO (1) | WO2018187439A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112126618B (en) * | 2019-06-24 | 2023-09-12 | 上海拜羡生物科技有限公司 | Method for obtaining human gallbladder stem cells and long-term in vitro culture |
WO2021065971A1 (en) * | 2019-09-30 | 2021-04-08 | テルモ株式会社 | Dilution buffer solution for cryopreserved cells |
CN115315182A (en) * | 2020-03-27 | 2022-11-08 | 上海我武干细胞科技有限公司 | Cell preservation solution and kit thereof |
CN112514892B (en) * | 2020-12-25 | 2022-06-14 | 广州赛莱拉干细胞科技股份有限公司 | Exosome cryopreservation protection solution and preparation method thereof |
US11735303B2 (en) | 2021-06-22 | 2023-08-22 | David Haase | Apparatus and method for determining a composition of a replacement therapy treatment |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992003046A1 (en) * | 1990-08-28 | 1992-03-05 | Somatix Therapy Corporation | Improved cell cryopreservation method |
JPH07255469A (en) * | 1994-03-17 | 1995-10-09 | Kurabo Ind Ltd | Frozen storage solution for mammalian cell |
EP1728857A3 (en) * | 2000-01-19 | 2007-04-11 | The University of North Carolina at Chapel Hill | Liver tissue source |
JP4705473B2 (en) * | 2003-11-06 | 2011-06-22 | 株式会社リプロセル | Stem cell cryopreservation method and system |
KR20200146043A (en) * | 2009-10-30 | 2020-12-31 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | Multipotent stem cells from the extrahepatic billary tree and methods of isolating same |
KR102493613B1 (en) * | 2010-05-07 | 2023-01-31 | 유니버시티 오브 노스캐롤라이나 앳 채플 힐 | Method of engrafting cells from solid tissues |
AU2015205872B2 (en) * | 2010-05-07 | 2017-07-06 | University Of North Carolina At Chapel Hill | Method of engrafting cells from solid tissues |
CN107075467B (en) * | 2014-09-19 | 2020-08-21 | 新加坡科技研究局 | Differentiation of hepatocyte-like cells from stem cells |
-
2018
- 2018-04-04 CN CN201880035544.8A patent/CN110913691A/en active Pending
- 2018-04-04 SG SG10202111093PA patent/SG10202111093PA/en unknown
- 2018-04-04 SG SG11201908905S patent/SG11201908905SA/en unknown
- 2018-04-04 AU AU2018249853A patent/AU2018249853A1/en not_active Abandoned
- 2018-04-04 RU RU2019135079A patent/RU2019135079A/en unknown
- 2018-04-04 EP EP18781383.7A patent/EP3612027A4/en active Pending
- 2018-04-04 KR KR1020197032291A patent/KR20190141168A/en not_active Application Discontinuation
- 2018-04-04 WO PCT/US2018/026038 patent/WO2018187439A1/en unknown
- 2018-04-04 JP JP2019555109A patent/JP2020516257A/en active Pending
- 2018-04-04 CA CA3057883A patent/CA3057883A1/en active Pending
- 2018-04-04 US US15/945,422 patent/US20180295834A1/en not_active Abandoned
- 2018-04-04 BR BR112019020699-0A patent/BR112019020699A2/en not_active IP Right Cessation
-
2019
- 2019-09-24 IL IL269602A patent/IL269602B/en unknown
-
2021
- 2021-09-08 US US17/469,553 patent/US20220232820A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110913691A (en) | 2020-03-24 |
RU2019135079A (en) | 2021-05-06 |
EP3612027A4 (en) | 2021-02-24 |
AU2018249853A1 (en) | 2019-10-31 |
CA3057883A1 (en) | 2018-10-11 |
RU2019135079A3 (en) | 2021-08-03 |
KR20190141168A (en) | 2019-12-23 |
BR112019020699A2 (en) | 2020-05-12 |
IL269602A (en) | 2019-11-28 |
SG10202111093PA (en) | 2021-11-29 |
IL269602B (en) | 2022-06-01 |
WO2018187439A1 (en) | 2018-10-11 |
JP2020516257A (en) | 2020-06-11 |
US20180295834A1 (en) | 2018-10-18 |
EP3612027A1 (en) | 2020-02-26 |
US20220232820A1 (en) | 2022-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908905SA (en) | Cryopreservation method | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201805420SA (en) | Antibodies and conjugates thereof | |
SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201808176TA (en) | Gene therapy for treating mucopolysaccharidosis type ii | |
SG11201408261UA (en) | Syringe | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
SG11201408521WA (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201901203PA (en) | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients | |
SG11201909561RA (en) | Octree-based convolutional neural network | |
SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |